Navigation Links
Regeneron Reports Third Quarter 2009 Financial and Operating Results
Date:11/3/2009

ve Growth Factor (NGF), a novel target for pain, began a dose ranging study in osteoarthritis of the knee. Trial results are expected during the first half of 2010. A Phase 1 study of REGN475 in healthy volunteers is also continuing, and Phase 1 studies are in progress with REGN88, an antibody to the interleukin-6 receptor (IL-6R) that is being evaluated in rheumatoid arthritis, and REGN421, an antibody to Delta-like ligand-4 (Dll4) that is being studied in patients with advanced malignancies. REGN475, REGN88, and REGN421 are fully human monoclonal antibodies generated by Regeneron using the VelocImmune® technology and developed within the Company's human antibody collaboration with sanofi-aventis. Regeneron and sanofi-aventis expect to enter two more human monoclonal antibodies into clinical development this year and to advance an average of two to three into clinical development each year thereafter over the next several years.

Financial Results

Revenues

Total revenues increased to $117.5 million in the third quarter of 2009 from $65.6 million in the same quarter of 2008 and increased to $282.5 million for the first nine months of 2009 from $182.6 million for the same period of 2008. The Company's revenue was comprised of contract research and development revenue, a 2009 research progress payment, technology licensing revenue, and net product sales.

Contract Research and Development Revenue

Contract research and development revenue relates primarily to the Company's aflibercept and antibody collaborations with sanofi-aventis and the Company's VEGF Trap-Eye collaboration with Bayer HealthCare. Contract research and development revenue for the three and nine months ended September 30, 2009 and 2008 consisted of the following:

                                       Three months ended  Nine months ended
                                          September 30,      S
'/>"/>
SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related medicine technology :

1. Bayer and Regeneron Dose First Patient in Second Phase 3 Study for VEGF Trap-Eye in Wet Age-Related Macular Degeneration
2. Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion
3. Enrollment Completed in Regeneron and Bayer HealthCare Phase 3 Studies of VEGF Trap-Eye in Neovascular Age-Related Macular Degeneration (Wet AMD)
4. Regeneron Announces Presentation at the 18th Annual Credit Suisse Healthcare Conference
5. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
6. Spherix Reports Second Quarter Earnings
7. Tapestry Reports Second Quarter 2007 Results
8. Callisto Reports on Second-Quarter 2007 Milestones
9. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
10. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
11. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... LUTHERVILLE, Md. , Aug. 20, 2014 /PRNewswire/ ... today lauded the latest results achieved by the ... known as the National Precursor Log Exchange (NPLEx), ... enforcement officials track down meth offenders and make ... in Kentucky blocked the ...
(Date:8/20/2014)... Aug. 20, 2014 Reportlinker.com ... report is available in its catalogue: ... Infection Control (Sterilization, Disinfection, Testing and ... Given the cost ... demand has increased for solutions that ...
(Date:8/20/2014)... Reportbuyer.com has added a new market research report: ... This report analyzes the worldwide markets ... Product Segments: Implantable/Internal Cardiac Defibrillators, and External Defibrillators. The ... Canada , Japan , ... , Middle East & ...
Breaking Medicine Technology:Kentucky's Stop-Sale System Achieves Significant Results In Battle Against Meth 2The Market for Hospital-Acquired Infection Control (Sterilization, Disinfection, Testing and Treatment) 2The Market for Hospital-Acquired Infection Control (Sterilization, Disinfection, Testing and Treatment) 3The Market for Hospital-Acquired Infection Control (Sterilization, Disinfection, Testing and Treatment) 4The Market for Hospital-Acquired Infection Control (Sterilization, Disinfection, Testing and Treatment) 5The Market for Hospital-Acquired Infection Control (Sterilization, Disinfection, Testing and Treatment) 6Global Cardiac Defibrillators Industry 2Global Cardiac Defibrillators Industry 3Global Cardiac Defibrillators Industry 4Global Cardiac Defibrillators Industry 5Global Cardiac Defibrillators Industry 6Global Cardiac Defibrillators Industry 7Global Cardiac Defibrillators Industry 8Global Cardiac Defibrillators Industry 9Global Cardiac Defibrillators Industry 10Global Cardiac Defibrillators Industry 11Global Cardiac Defibrillators Industry 12Global Cardiac Defibrillators Industry 13Global Cardiac Defibrillators Industry 14Global Cardiac Defibrillators Industry 15Global Cardiac Defibrillators Industry 16Global Cardiac Defibrillators Industry 17Global Cardiac Defibrillators Industry 18Global Cardiac Defibrillators Industry 19Global Cardiac Defibrillators Industry 20
... SILVER SPRING, Md., April 15, 2011 The U.S. ... given alone or in combination with methotrexate, for ... (SJIA) in children ages 2 years and older. ... SJIA, or Still,s disease, is a rare, potentially ...
... Inc., owner and operator of both Reptrax and VendorClear, ... leading vendor compliance solution. With the acquisition of Status ... industry,s credentialing efforts onto one standardized platform. Status Blue, ... care and grounded credentialing principles that are shared by ...
Cached Medicine Technology:FDA Approves Actemra to Treat Rare Form of Juvenile Arthritis 2FDA Approves Actemra to Treat Rare Form of Juvenile Arthritis 3IntelliCentrics, Inc. Acquires Hospital Vendor Credentialing Solution Status Blue, LLC 2IntelliCentrics, Inc. Acquires Hospital Vendor Credentialing Solution Status Blue, LLC 3
(Date:8/20/2014)... News) -- Loss of brain cells that act as ... have trouble falling and staying asleep, a new study ... especially severe and often results in nighttime confusion and ... data from the Rush Memory and Aging Project, which ... and are being followed until death, at which point ...
(Date:8/20/2014)... 2014 The Board of Directors of ... is pleased to announce the expansion of its ... China and the surrounding region. In support of ... AIA has relocated to the firm’s office in ... planning and design and to better support regional clients. ...
(Date:8/20/2014)... spawning grounds through fast-moving waters may be at risk, ... , When salmon encounter turbulent, fast-moving water such ... must move upstream using a behaviour known as "burst ... "Days after sockeye passed through extremely fast-moving water, we ... from their spawning grounds," said Nicholas Burnett, a research ...
(Date:8/20/2014)... 2014) Research from Columbia University Medical Center shows ... cancer growth and that blocking nerve signals using surgery ... the disease. The study was conducted by the laboratory ... Chen, MD, PhD, in Norway and is published in ... "Scientists have long observed that human and mouse cancers ...
(Date:8/20/2014)... 2014 Quincy Bioscience, a Wisconsin-based biotech ... of the fastest growing private companies in the ... No. 2,941, Quincy Bioscience is honored again to be ... States. , Quincy Bioscience is manufacturer of Prevagen brand ... protein originally discovered in jellyfish and clinically shown to ...
Breaking Medicine News(10 mins):Health News:Seniors' Sleep Woes May Be Linked to Loss of Brain Cells 2Health News:Perkins Eastman Expands Presence in China 2Health News:Perkins Eastman Expands Presence in China 3Health News:Salmon forced to 'sprint' less likely to survive migration 2Health News:Severing nerves may shrink stomach cancers: Botox injections slow growth of tumors in mice 2Health News:Quincy Bioscience Recognized in Inc. 500|5000 List of America’s Fastest Growing Companies for Third Consecutive Year 2
... The following fact sheet was released today by ... We Fail Partnership (AARP, Business Roundtable, National Federation of ... Divided We Fail, we urge you to act promptly ... Program (SCHIP). Our nation has a duty to give ...
... journal report:Study highlights:-- Cholesterol-lowering drug adherence drops with ... of going for 90 straight days without medication ... all co-payment group and twice as high in ... to the exempt group (received prescriptions without a ...
... Benzoyl Peroxide Wash to Utilize MICROSPONGE(R) Delivery SystemCARLSBAD, ... the launch of NeoBenz Micro Wash, ... with the MICROSPONGE (R) delivery system, for ... NeoBenz Micro Wash contains 7% benzoyl ...
... 29 Years of Experience with Complex Rehab MarketHOUSTON, Jan. ... almost 30 years of experience, has joined Alliance ... fastest growing accredited complex rehab companies. Kieschnik is an ... Technology Supplier (CRTS) in Houston, Texas, for ASM ( ...
... Association rapid access journal reportStudy highlights:, , ... determine the odds of having cardiovascular disease within 10 years may ... Most adults 50 years and younger have a low ... for heart disease. , Researchers ...
... urban areas , , WEDNESDAY, Jan. 14 (HealthDay News) -- ... are making a comeback in some urban areas, a new ... where infestations have grown in recent years, appear to have ... pyrethroid toxins, such as deltamethrin, commonly used against them, according ...
Cached Medicine News:Health News:Health Care For 11 Million Children 2Health News:Health Care For 11 Million Children 3Health News:Health Care For 11 Million Children 4Health News:Co-Payment Increases Result in Gaps in Veterans' Prescription Usage 2Health News:Co-Payment Increases Result in Gaps in Veterans' Prescription Usage 3Health News:Co-Payment Increases Result in Gaps in Veterans' Prescription Usage 4Health News:SkinMedica(R) Launches NeoBenz(R) Micro Wash for Acne 2Health News:SkinMedica(R) Launches NeoBenz(R) Micro Wash for Acne 3Health News:Veteran Rehab Specialist, Anne Kieschnik, Joins Fast-Growing Alliance Seating & Mobility In Texas 2Health News:Veteran Rehab Specialist, Anne Kieschnik, Joins Fast-Growing Alliance Seating & Mobility In Texas 3Health News:Half of Adults 50 and Younger With Low 10-Year Risk of CVD Have High Lifetime Risk 2Health News:Half of Adults 50 and Younger With Low 10-Year Risk of CVD Have High Lifetime Risk 3Health News:Bed Bugs, Nearly Eradicated, Make a Comeback 2
For primary and revision cases...
The Protract stem offers a press-fit option which will allow choice of standard or lateralized neck offsets while keeping a consistent leg length....
Standard Erlanger hip stem....
Cemented foundation 460 series....
Medicine Products: